This company listing is no longer active
2160 Stock Overview
A medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2160 from our risk checks.
MicroPort CardioFlow Medtech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.66 |
| 52 Week High | HK$1.97 |
| 52 Week Low | HK$0.58 |
| Beta | 0.37 |
| 11 Month Change | -10.81% |
| 3 Month Change | -30.53% |
| 1 Year Change | -61.63% |
| 33 Year Change | -90.50% |
| 5 Year Change | n/a |
| Change since IPO | -96.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2160 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 6.5% | -2.6% | -1.0% |
| 1Y | -61.6% | -34.1% | 15.0% |
Return vs Industry: 2160 underperformed the Hong Kong Medical Equipment industry which returned -44.8% over the past year.
Return vs Market: 2160 underperformed the Hong Kong Market which returned -3.3% over the past year.
Price Volatility
| 2160 volatility | |
|---|---|
| 2160 Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2160's share price has been volatile over the past 3 months.
Volatility Over Time: 2160's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 483 | Jeffrey R Lindstrom | www.cardioflowmedtech.com |
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, Angelguide tip-preshaped super sti¬ff guidewire, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company also provides technical consultation and technical services for medical devices clinical trial.
MicroPort CardioFlow Medtech Corporation Fundamentals Summary
| 2160 fundamental statistics | |
|---|---|
| Market cap | HK$1.59b |
| Earnings (TTM) | -HK$381.86m |
| Revenue (TTM) | HK$419.46m |
4.0x
P/S Ratio-4.4x
P/E RatioIs 2160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2160 income statement (TTM) | |
|---|---|
| Revenue | CN¥382.91m |
| Cost of Revenue | CN¥111.38m |
| Gross Profit | CN¥271.53m |
| Other Expenses | CN¥620.13m |
| Earnings | -CN¥348.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 70.91% |
| Net Profit Margin | -91.04% |
| Debt/Equity Ratio | 1.2% |
How did 2160 perform over the long term?
See historical performance and comparison